TN2009000342A1 - Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors - Google Patents

Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors

Info

Publication number: TN2009000342A1
Authority: TN; Tunisia
Prior art keywords: kinase inhibitors; synthesis; group; aminothiazole compounds; inhibitors
Prior art date: 2007-02-13

Application number

TNP2009000342A

Other languages

English (en)

Inventor

Alain Moussy

Philippe Reginault

Francois Bellamy

Anne Lermet

Original Assignee

Ab Science

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-13

Filing date

2009-08-11

Publication date

2010-12-31

2009-08-11 Application filed by Ab Science filed Critical Ab Science

2010-12-31 Publication of TN2009000342A1 publication Critical patent/TN2009000342A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Catalysts (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

TNP2009000342A 2007-02-13 2009-08-11 Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors TN2009000342A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88958707P	2007-02-13	2007-02-13
PCT/EP2008/051704 WO2008098949A2 (fr)	2007-02-13	2008-02-13	Procédé de synthèse de composés 2-aminothiazole comme inhibiteurs de kinase

Publications (1)

Publication Number	Publication Date
TN2009000342A1 true TN2009000342A1 (en)	2010-12-31

Family

ID=39332208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000342A TN2009000342A1 (en)	2007-02-13	2009-08-11	Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors

Country Status (23)

Country	Link
US (3)	US8153792B2 (fr)
EP (2)	EP2118099B1 (fr)
JP (2)	JP5568312B2 (fr)
KR (1)	KR20090110851A (fr)
CN (2)	CN101657446B (fr)
AR (1)	AR065337A1 (fr)
AT (1)	ATE515506T1 (fr)
AU (1)	AU2008214679A1 (fr)
BR (1)	BRPI0807626B1 (fr)
CA (2)	CA2677586C (fr)
ES (2)	ES2369617T3 (fr)
HR (2)	HRP20110709T1 (fr)
IL (1)	IL200320A0 (fr)
MA (1)	MA31180B1 (fr)
MX (1)	MX2009008665A (fr)
NZ (1)	NZ578944A (fr)
PL (2)	PL2118099T3 (fr)
RU (2)	RU2456285C2 (fr)
SI (2)	SI2366703T1 (fr)
TN (1)	TN2009000342A1 (fr)
TW (1)	TWI406862B (fr)
WO (1)	WO2008098949A2 (fr)
ZA (1)	ZA200905981B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2294344T3 (es)	2002-08-02	2008-04-01	Ab Science	2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit.
US8450302B2 (en)	2002-08-02	2013-05-28	Ab Science	2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
TW201202232A (en)	2010-01-28	2012-01-16	Ab Science	Treatment of GIST with masitinib
AR080096A1 (es)	2010-02-01	2012-03-14	Ab Science	Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
AR080380A1 (es)	2010-03-09	2012-04-04	Ab Science	Tratamiento de la demencia tipo alzheimer con masitinib
WO2011131705A1 (fr)	2010-04-20	2011-10-27	Ab Science	Traitement de la sclérose en plaques à l'aide de masitinib
AR081772A1 (es)	2010-06-02	2012-10-17	Ab Science	Tratamiento de la artritis reumatoide con masitinib
US20140147415A1 (en)	2010-11-05	2014-05-29	Ab Science	Treatment of mastocytosis with masitinib
US10045978B2 (en)	2010-11-05	2018-08-14	Ab Science	Treatment of mastocytosis with masitinib
WO2012104402A1 (fr) *	2011-02-04	2012-08-09	Ab Science	Traitement de l'asthme sévère persistant avec le masitinib
WO2012136732A1 (fr)	2011-04-08	2012-10-11	Ab Science	Traitement du myélome multiple au moyen de mastinib
EP2903616B8 (fr)	2012-10-04	2018-02-07	AB Science	Utilisation du masitinib en combinaison avec la gemcitabine pour traiter un sous-groupe de patients souffrant d'un cancer du pancréas
TW201605449A (zh)	2013-12-02	2016-02-16	Ａｂ化學公司	馬賽替尼治療結腸直腸癌的用途
EP2886543A1 (fr)	2013-12-18	2015-06-24	Sandoz Ag	Forme cristalline de masitinibe
US20170196853A1 (en)	2014-06-02	2017-07-13	Ab Science	Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
CN105585556A (zh) *	2014-11-13	2016-05-18	连云港杰瑞药业有限公司	一种伊马替尼的合成方法
CN106794179A (zh) *	2015-07-29	2017-05-31	苏州晶云药物科技有限公司	马赛替尼甲磺酸盐的新晶型及其制备方法
CA3000894A1 (fr)	2015-10-05	2017-04-13	Ab Science	Traitement de la mastocytose systemique grave par le masitinib
EA038531B1 (ru)	2016-03-25	2021-09-10	Аб Сьянс	Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб
EP3601278B1 (fr)	2017-03-31	2022-10-26	Sandoz AG	Forme cristalline de masitinibe
US10696638B2 (en)	2017-12-26	2020-06-30	Industrial Technology Research Institute	Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
WO2021099616A1 (fr)	2019-11-22	2021-05-27	Ab Science	Masitinib pour le traitement de la drépanocytose
EP3831384A1 (fr)	2019-12-02	2021-06-09	AB Science	Utilisation de masitinib pour le traitement de l'asthme éosinophile
WO2021165472A1 (fr)	2020-02-20	2021-08-26	Ab Science	Masitinib pour le traitement d'une sous-population de patients souffrant de sclérose en plaques
CN115867278B (zh)	2020-04-10	2025-02-28	Ab科学有限公司	马赛替尼用于治疗covid-19的用途
WO2022129410A1 (fr)	2020-12-16	2022-06-23	Ab Science	Masitinib pour le traitement de la maladie d'alzheimer
CA3217490A1 (fr)	2021-05-17	2022-11-24	Alain Moussy	Masitinib pour le traitement du cancer de la prostate resistant a la castration
CN115850258B (zh) *	2022-12-27	2024-09-24	东北林业大学	一种马赛替尼的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3299087A (en) *	1961-04-24	1967-01-17	Geigy Chem Corp	Nu, nu'-bis-(thiazolyl)-phenylenediamines
IL132736A0 (en) *	1997-05-22	2001-03-19	Searle & Co	3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
CO4940418A1 (es) *	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9718913D0 (en) *	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
US6569878B1 (en) *	1997-10-27	2003-05-27	Agouron Pharmaceuticals Inc.	Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors
US6114365A (en) *	1999-08-12	2000-09-05	Pharmacia & Upjohn S.P.A.	Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP1218376B1 (fr) *	1999-09-10	2005-11-09	Merck & Co., Inc.	Inhibiteurs de tyrosine kinase
EP1401412A2 (fr)	2001-06-29	2004-03-31	AB Science	Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale
US20030091974A1 (en)	2001-06-29	2003-05-15	Alain Moussy	Method for screening compounds capable of depleting mast cells
US7727731B2 (en)	2001-06-29	2010-06-01	Ab Science	Potent, selective and non toxic c-kit inhibitors
PT1401413E (pt)	2001-06-29	2007-02-28	Ab Science	Uso de inibidores da tirosina cinase para tratar doenças alérgicas
DK1401415T3 (da)	2001-06-29	2006-10-16	Ab Science	Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
ATE401079T1 (de)	2001-06-29	2008-08-15	Ab Science	Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
WO2003004007A2 (fr)	2001-06-29	2003-01-16	Ab Science	Utilisation d'inhibiteurs de tyrosine kinases pour traiter les maladies intestinales inflammatoires (mii)
US20050054617A1 (en)	2001-06-29	2005-03-10	Alain Moussy	Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
US20040266771A1 (en)	2001-06-29	2004-12-30	Alain Moussy	Use of tyrosine kinase inhibitors for treating bone loss
WO2003002107A2 (fr)	2001-06-29	2003-01-09	Ab Science	Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de la sclerose en plaques
US20040242612A1 (en)	2001-09-20	2004-12-02	Alain Moussy	Use of tyrosine kinase inhibitors for promoting hair growth
ATE388711T1 (de)	2001-09-20	2008-03-15	Ab Science	C-kithemmer zur behandlung von bakteriellen infektionen
EP1427422A1 (fr)	2001-09-20	2004-06-16	AB Science	Utilisation d'inhibiteurs de tyrosine kinase pour blanchir la peau humaine et traiter des troubles associes a un dysfonctionnement des melanocytes
DE60307237T2 (de)	2002-02-27	2007-10-18	Ab Science	Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
AU2003209933A1 (en)	2002-02-27	2003-09-09	Ab Science	Use of tyrosine kinase inhibitors for treating substance use disorders
AU2003273579A1 (en) *	2002-05-29	2003-12-19	Amgen Inc.	2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders
ES2294344T3 (es) *	2002-08-02	2008-04-01	Ab Science	2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit.
SE0202462D0 (sv) *	2002-08-14	2002-08-14	Astrazeneca Ab	Novel use
CA2515215A1 (fr) *	2003-02-10	2004-08-26	Amgen Inc.	Ligands du recepteur vanilloide et leur utilisation dans des traitements
DE602004013283D1 (de)	2003-02-27	2008-06-05	Ab Science	Diagnostisches verfahren der mastozytose
FR2854158B1 (fr) *	2003-04-25	2006-11-17	Sanofi Synthelabo	Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
WO2005011597A2 (fr) *	2003-07-29	2005-02-10	Irm Llc	Composes et compositions utilises en tant qu'inhibiteurs des proteines kinases
US20070032521A1 (en)	2003-08-15	2007-02-08	Ab Science	Use of c-kit inhibitors for treating type II diabetes
US7363881B2 (en)	2003-11-06	2008-04-29	Nova-Tech Engineering, Inc.	Beak treatment with tongue protection
AU2004309248B2 (en) *	2003-12-25	2009-11-05	Nippon Shinyaku Co., Ltd.	Amide derivative and medicine
US7650848B2 (en) *	2004-02-17	2010-01-26	University Of Florida Research Foundation, Inc.	Surface topographies for non-toxic bioadhesion control
WO2005115385A1 (fr) *	2004-05-24	2005-12-08	Ab Science	Utilisation d'inhibiteurs de c-kit pour le traitement de l'acne
TW200702876A (en) *	2005-07-04	2007-01-16	Avermedia Tech Inc	Projector device capable of sychronously encoding audio and video to become AV sychronous paly file

2008
- 2008-02-13 AR ARP080100620A patent/AR065337A1/es active IP Right Grant
- 2008-02-13 US US12/526,827 patent/US8153792B2/en active Active
- 2008-02-13 JP JP2009549405A patent/JP5568312B2/ja active Active
- 2008-02-13 SI SI200831294T patent/SI2366703T1/sl unknown
- 2008-02-13 MX MX2009008665A patent/MX2009008665A/es active IP Right Grant
- 2008-02-13 CN CN2008800049044A patent/CN101657446B/zh active Active
- 2008-02-13 KR KR1020097016822A patent/KR20090110851A/ko not_active Withdrawn
- 2008-02-13 RU RU2009132186/04A patent/RU2456285C2/ru active
- 2008-02-13 CA CA2677586A patent/CA2677586C/fr active Active
- 2008-02-13 TW TW097105021A patent/TWI406862B/zh not_active IP Right Cessation
- 2008-02-13 WO PCT/EP2008/051704 patent/WO2008098949A2/fr active Application Filing
- 2008-02-13 EP EP08708929A patent/EP2118099B1/fr active Active
- 2008-02-13 NZ NZ578944A patent/NZ578944A/en unknown
- 2008-02-13 AT AT08708929T patent/ATE515506T1/de not_active IP Right Cessation
- 2008-02-13 SI SI200830399T patent/SI2118099T1/sl unknown
- 2008-02-13 AU AU2008214679A patent/AU2008214679A1/en not_active Abandoned
- 2008-02-13 ES ES08708929T patent/ES2369617T3/es active Active
- 2008-02-13 ES ES11170200.7T patent/ES2522169T3/es active Active
- 2008-02-13 PL PL08708929T patent/PL2118099T3/pl unknown
- 2008-02-13 CA CA2970628A patent/CA2970628C/fr active Active
- 2008-02-13 PL PL11170200T patent/PL2366703T3/pl unknown
- 2008-02-13 CN CN201310141370.2A patent/CN103342701B/zh active Active
- 2008-02-13 EP EP11170200.7A patent/EP2366703B1/fr active Active
- 2008-02-13 BR BRPI0807626-0A patent/BRPI0807626B1/pt active IP Right Grant
2009
- 2009-08-10 IL IL200320A patent/IL200320A0/en unknown
- 2009-08-11 TN TNP2009000342A patent/TN2009000342A1/fr unknown
- 2009-08-11 MA MA32161A patent/MA31180B1/fr unknown
- 2009-08-28 ZA ZA2009/05981A patent/ZA200905981B/en unknown
2011
- 2011-10-05 HR HR20110709T patent/HRP20110709T1/hr unknown
2012
- 2012-03-08 US US13/415,249 patent/US8492545B2/en active Active
- 2012-04-12 RU RU2012114234/04A patent/RU2491286C1/ru active
2013
- 2013-05-10 US US13/891,639 patent/US8940894B2/en active Active
- 2013-05-30 JP JP2013113789A patent/JP5784073B2/ja active Active
2014
- 2014-10-15 HR HRP20140986AT patent/HRP20140986T1/hr unknown

Also Published As

Publication number	Publication date
TW200848419A (en)	2008-12-16
PL2118099T3 (pl)	2011-12-30
US20120196871A1 (en)	2012-08-02
RU2009132186A (ru)	2011-03-20
ES2369617T3 (es)	2011-12-02
EP2118099B1 (fr)	2011-07-06
CA2677586A1 (fr)	2008-08-21
ATE515506T1 (de)	2011-07-15
US8153792B2 (en)	2012-04-10
MX2009008665A (es)	2009-08-21
ZA200905981B (en)	2010-11-24
JP5568312B2 (ja)	2014-08-06
US20100121063A1 (en)	2010-05-13
JP2010518141A (ja)	2010-05-27
TWI406862B (zh)	2013-09-01
US20130289045A1 (en)	2013-10-31
CA2970628C (fr)	2019-08-27
CN101657446A (zh)	2010-02-24
RU2456285C2 (ru)	2012-07-20
CA2970628A1 (fr)	2008-08-21
JP5784073B2 (ja)	2015-09-24
AR065337A1 (es)	2009-06-03
HRP20140986T1 (hr)	2014-11-21
BRPI0807626B1 (pt)	2022-03-03
IL200320A0 (en)	2010-04-29
NZ578944A (en)	2011-03-31
EP2366703A1 (fr)	2011-09-21
BRPI0807626A2 (pt)	2014-11-25
SI2118099T1 (sl)	2011-11-30
KR20090110851A (ko)	2009-10-22
JP2013177437A (ja)	2013-09-09
CN103342701A (zh)	2013-10-09
WO2008098949A3 (fr)	2008-10-02
EP2118099A2 (fr)	2009-11-18
HRP20110709T1 (hr)	2011-11-30
US8492545B2 (en)	2013-07-23
MA31180B1 (fr)	2010-02-01
CN101657446B (zh)	2013-05-15
ES2522169T3 (es)	2014-11-13
WO2008098949A2 (fr)	2008-08-21
RU2491286C1 (ru)	2013-08-27
US8940894B2 (en)	2015-01-27
CN103342701B (zh)	2016-09-21
CA2677586C (fr)	2017-07-25
EP2366703B1 (fr)	2014-07-30
AU2008214679A1 (en)	2008-08-21
SI2366703T1 (sl)	2014-10-30
PL2366703T3 (pl)	2015-02-27

Publication	Publication Date	Title
TN2009000342A1 (en)	2010-12-31	Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors
SI1711481T2 (sl)	2013-10-30	Postopek za pripravo 2-aminotiazoli-5-aromatiäśnih karboksamidov kot kinazni inhibitorji
HK1110588A1 (en)	2008-07-18	Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
UA109775C2 (xx)	2015-10-12	N-вмісні гетероарильні похідні як інгібітори jak3-кінази
EA200870192A1 (ru)	2009-12-30	Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
DE602007009085D1 (de)	2010-10-21	Neues verfahren zur synthese von 2-aminooxazolverbindungen
MX2009011213A (es)	2009-11-02	Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
EA200701176A1 (ru)	2008-02-28	Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
TW201129556A (en)	2011-09-01	Novel antiplatelet agent
TNSN08276A1 (en)	2009-10-30	Pyrimidinyl aryl urea derivatives being fgf inhibitors
BRPI0814065B8 (pt)	2021-05-25	derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
RS51661B (en)	2011-10-31	NEW DIOSMETHINE DERIVATIVES, THE PROCEDURE FOR THEIR MAKING AND THE PHARMACEUTICAL MIXTURES CONTAINING THEM
UY31750A (es)	2009-12-14	Compuestos y composiciones como inhibidores de quinasa
TW200738685A (en)	2007-10-16	Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MY155230A (en)	2015-09-30	Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine
WO2005076990A3 (fr)	2005-11-24	Procede de preparation de 2-aminothiazole-5-carboxamides utiles en tant qu'inhibiteurs de kinase
SE0400850D0 (sv)	2004-03-31	Novel Compounds
MY153042A (en)	2014-12-31	Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
ATE513818T1 (de)	2011-07-15	Chinazolinonderivate als tubulinpolymerisationshemmer
SE0403085D0 (sv)	2004-12-17	Novel componds
ATE364384T1 (de)	2007-07-15	Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
EA201590069A1 (ru)	2015-05-29	Пиримидиноновые производные в качестве антималярийных средств
JO3248B1 (ar)	2018-09-16	عملية لتحضير إنزيمات مثبطة من نوع c-fms
SE0403086D0 (sv)	2004-12-17	Compounds
MY150988A (en)	2014-03-31	Novel derivatives of ( bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors